[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Helioson Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100641930",false,"NCT07658352","A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","An Open-label, First-in-human Dose Escalation and Dose Expansion Phase I\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HP-002 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group Performance Status (ECOG) of 0-2.\n* Patients with relapsed or refractory B-cell non-Hodgkin lymphoma subtypes (CLL\u002FSLL, MCL, MZL, DLBCL, FL, WM, and PCNSL).\n\nExclusion Criteria:\n\n* Prior use of a BTK protein degrader.","ALL","18 Years",{"count":18,"type":19},114,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","This is an open-label, first-in-human dose escalation and dose expansion Phase I\u002FII clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HP-002 in patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma This study consists of two phases: a dose-exploration phase and a dose-expansion phase.\n\nThe safety and tolerability of HP-002 will be evaluated in Phase 1 study, as well as the maximum tolerated dose (MTD) and the recommended dose level for Phase 2 study will be determined.\n\nThe efficacy of HP-002 will be evaluated in Phase 2 study.",[26],"B-Cell Non-Hodgkin Lymphoma","NOT_YET_RECRUITING","2026-06-16",{"date":30,"type":31},"2026-06-22","ACTUAL",{"date":33,"type":19},"2026-06-26",{"date":35,"type":19},"2031-06-26",{"name":37,"class":38},"Shanghai Helioson Pharmaceutical Co., Ltd.","INDUSTRY",""]